Table 1.
Characteristics and methodological quality of included studies.
| Study ID | Sample | Diagnosis standard | Intervention | Control | Course (week) | Outcome measure |
|---|---|---|---|---|---|---|
| Wang et al., 1998 [63] | 98 | 1999 WHO-ISH GMH; TCM diagnostic criteria (unclear) | modified TGY (1 dose/d) + control | captopril (25 mg tid) | 4 | BP; TCM zheng |
| Ren and Zhao, 2012 [64] | 60 | 1999 WHO-ISH GMH; GCRNDTCM | modified TGY (300 mL/d) + control | nifedipine sustained release tablets (10 mg bid) | 6 | BP |
| Fu, 2005 [65] | 116 | 1999 WHO-ISH GMH; TCM diagnostic criteria (unclear) | modified TGY (250 mL/d) + control | enalapril (10 mg bid) | 2 | BP |
| Qin, 2010 [66] | 45 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | antihypertensive drugs (no detailed information) | 4 | BP |
| Hu et al., 2009 [67] | 39 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + captopril | captopril (12.5–25 mg bid) + TGY placebo | 4 | BP |
| Sun and Huang, 2007 [68] | 60 | hypertension diagnostic criteria (unclear); GCRNDTCM | TGY (1 dose/d) + control | hydrochlorothiazide (12.5 mg bid) | 4 | BP |
| Wang et al., 2008 [69] | 80 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | captopril (25 mg tid) | 4 | BP; TCM zheng |
| Fang et al., 2008 [70] | 60 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | captopril (25 mg tid) | 4 | BP |
| Li, 2006 [71] | 80 | 1999 WHO-ISH GMH; CIM | modified TGY (1 dose/d) + control | captopril (12.5 mg bid) | 4 | BP; TCM zheng |
| Liu, 2011 [72] | 86 | 1999 WHO-ISH GMH; GCRNDTCM | modified TGY (1 dose/d) + control | amlodipine besylate (5 mg qd) | 8 | BP; TCM zheng |
| Liu et al., 2009 [73] | 60 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | perindopril (25 mg tid) | 4 | BP; TCM zheng |
| Chen, 2009 [74] | 100 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | captopril (25 mg tid) | 6 | BP; TCM zheng |
| Zhang and Yang, 2011 [75] | 60 | CGMH-2005; GCRNDTCM | modified TGY (1 dose/d) + control | amlodipine besylate (5 mg qd) + lisinopril (10 mg qd) | 4 | BP; TCM zheng |
| Liu and Li, 2011 [76] | 100 | 1999 WHO-ISH GMH; CIM | TGY (1 dose/d) + control | nifedipine sustained release tablets (10 mg bid) | 4 | BP |
| Wei, 2012 [77] | 98 | 1999 WHO-ISH GMH; TCM diagnostic criteria (unclear) | TGY (1 dose/d) + control | nifedipine (10 mg bid) | 4 | BP |
| Li, 2011 [78] | 120 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | levamlodipine (5 mg qd) | 4 | BP |
| Lin and Liu, 2010 [79] | 94 | CGMH-2005; GCRNDTCM | TGY (1 dose/d) + control | telmisartan (20 mg qd) | 4 | BP |
| Zhou and Zhang, 2011 [80] | 72 | 1999 WHO-ISH GMH; GCRNDTCM | modified TGY (1 dose/d) + control | captopril (25 mg bid) | 4 | BP |
| Chen, 2008 [81] | 100 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | captopril (25 mg tid) | 6 | BP; TCM zheng |
| Du, 2012 [82] | 100 | CGMH-1999; GCRNDTCM | modified TGY (1 dose/d) + control | captopril (25 mg tid) | 4 | BP |
| Cheng, 2010 [83] | 100 | 1999 WHO-ISH GMH; GCRNDTCM | modified TGY (1 dose/d) + control | enalapril (10 mg qd) | 12 | BP |
| Zhu, 2009 [84] | 80 | 1999 WHO-ISH GMH; GCRNDTCM | TGY (1 dose/d) + control | captopril (25 mg tid) | 4 | BP |